early setting

Oncology

ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.

News

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.